AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27126144 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-question protocol
Number of subjects: 48
Study 27126144 — intervention group
Group type: COMPARATOR
Intervention: Single open-ended question
Number of subjects: 48
Study 24738111 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional antipsychotics (perphenazine, sulpiride, chlorpromazine)
Number of subjects: 163
Study 24738111 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (clozapine, quetiapine, aripiprazole)
Number of subjects: 163
Study 24738111 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 163
Study 22853887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy intervention program (10-week duration)
Number of subjects: 19
Study 22853887 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 19
Study 20457363 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR SN60D3 (+4.00 D add)
Number of subjects: 40
Study 20457363 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR SN6AD3 (+4.00 D add)
Number of subjects: 40
Study 20457363 — intervention group
Group type: EXPERIMENTAL
Intervention: Acri.LISA 366D (+3.75 D add)
Number of subjects: 40
Study 20457363 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR SN6AD1 (+3.00 D add)
Number of subjects: 40
Study 17942205 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure at 0.5 ppm with peaks of 1.0 ppm
Number of subjects: 21
Study 17942205 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure at 0.3 ppm
Number of subjects: 21
Study 17942205 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure at 0.5 ppm plus peaks of 1.0 ppm
Number of subjects: 21
Study 17942205 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure at 0.3 and 0.5 ppm with co-exposure to ethyl acetate (EA)
Number of subjects: 21
Study 17942205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl acetate (EA) exposure only
Number of subjects: 21
Study 17942205 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality factor 'anxious'
Number of subjects: 21
Study 17942205 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure at 0.5 ppm with peaks of 1 ppm
Number of subjects: 21
Study 17942205 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde exposure at 0.3 ppm with peaks of 0.6 ppm
Number of subjects: 21
Study 17942205 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exposure symptom scores
Number of subjects: 21
Study 15880077 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic living-donor nephrectomy (L-LDN)
Number of subjects: 122
Study 15880077 — intervention group
Group type: COMPARATOR
Intervention: Open living-donor nephrectomy (O-LDN)
Number of subjects: 122
Study 12919638 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 166
Study 12919638 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment (control)
Number of subjects: 166
Study 10546391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemohyperthermia (IPCH) with an open procedure and upwards traction of the skin
Number of subjects: 32
Study 10546391 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal chemotherapy (IPIC) lasting four days
Number of subjects: 32
Study 10546391 — intervention group
Group type: COMPARATOR
Intervention: Procedures with closure of the abdomen
Number of subjects: 32
Study 10546391 — intervention group
Group type: COMPARATOR
Intervention: Intra-abdominal complications
Number of subjects: 32
Study 10546391 — intervention group
Group type: COMPARATOR
Intervention: Overall complications
Number of subjects: 32
Study 8756737 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis therapy for over 50 months
Number of subjects: 56
Study 8756737 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis therapy for less than 100 months
Number of subjects: 56
Study 8756737 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis therapy for over 100 months
Number of subjects: 56
Study 8756737 — intervention group
Group type: COMPARATOR
Intervention: Chronic renal insufficiency (compared to healthy controls)
Number of subjects: 56
Study 1861510 — intervention group
Group type: EXPERIMENTAL
Intervention: Wei Yang An (easing peptic-ulcer capsule)
Number of subjects: 0
Study 1861510 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 0
Study 6869735 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 4.5 mg/kg
Number of subjects: 20
Study 6869735 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.3 mg/kg
Number of subjects: 20
Study 30262599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediagnostic serum levels of 8-HETE (tertile 3 vs. 1)
Number of subjects: 313
Study 30262599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediagnostic serum levels of 12,13-DHOME
Number of subjects: 313
Study 30262599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediagnostic serum levels of 13-HODE
Number of subjects: 313
Study 30262599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediagnostic serum levels of 9-HODE
Number of subjects: 313
Study 30262599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediagnostic serum levels of 9,12,13-THOME
Number of subjects: 313
Study 29505528 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (RHE)
Number of subjects: 120
Study 29505528 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (Control)
Number of subjects: 120
Study 26811525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily plus trametinib 2 mg daily (150/2 group)
Number of subjects: 78
Study 26811525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 78
Study 25048383 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide (once-weekly subcutaneous)
Number of subjects: 0
Study 25048383 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (daily)
Number of subjects: 0
Study 22741450 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil + testosterone undecanoate
Number of subjects: 125
Study 22741450 — intervention group
Group type: COMPARATOR
Intervention: Testosterone undecanoate alone
Number of subjects: 125
Study 20231531 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0
Study 20231531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17898654 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome) 50 mg/m
Number of subjects: 14
Study 17898654 — intervention group
Group type: COMPARATOR
Intervention: Conventional daunorubicin 50 mg/m
Number of subjects: 14
Study 17898654 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome)
Number of subjects: 14
Study 17898654 — intervention group
Group type: COMPARATOR
Intervention: Conventional daunorubicin
Number of subjects: 14
Study 16328128 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed primary closure (Group 1, n = 20)
Number of subjects: 40
Study 16328128 — intervention group
Group type: COMPARATOR
Intervention: Primary closure (Group 2, n = 20)
Number of subjects: 40
Study 12488411 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with etoposide and cisplatin (EP)
Number of subjects: 436
Study 12488411 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with cyclophosphamide, epirubicin, and vincristine (CEV)
Number of subjects: 436
Study 12488411 — intervention group
Group type: EXPERIMENTAL
Intervention: EP in limited disease (LD) patients
Number of subjects: 436
Study 12488411 — intervention group
Group type: COMPARATOR
Intervention: CEV in limited disease (LD) patients
Number of subjects: 436
Study 12488411 — intervention group
Group type: EXPERIMENTAL
Intervention: EP in extensive disease (ED) patients
Number of subjects: 436
Study 12488411 — intervention group
Group type: COMPARATOR
Intervention: CEV in extensive disease (ED) patients
Number of subjects: 436
Study 12488411 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessments
Number of subjects: 436
Study 9816714 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA nalbuphine
Number of subjects: 60
Study 9816714 — intervention group
Group type: COMPARATOR
Intervention: PCA morphine
Number of subjects: 60
Study 7654161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 44
Study 7654161 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic Biofeedback (EMGBF)
Number of subjects: 44
Study 7654161 — intervention group
Group type: COMPARATOR
Intervention: Wait List Control (WLC)
Number of subjects: 44
Study 2653757 — intervention group
Group type: EXPERIMENTAL
Intervention: Two different diabetes treatment regimens
Number of subjects: 0
Study 787050 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline 0.25 mg
Number of subjects: 28
Study 787050 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline 0.5 mg
Number of subjects: 28
Study 787050 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine
Number of subjects: 28
Study 787050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31646723 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track ambulatory abscess pathway (FAAP)
Number of subjects: 100
Study 31646723 — intervention group
Group type: COMPARATOR
Intervention: Pre-ambulatory care pathway
Number of subjects: 100
Study 30629126 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein weight loss program (1.2-1.5 g/kg/d)
Number of subjects: 96
Study 28921537 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie technique
Number of subjects: 257
Study 26983578 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans' In‐home Programme (VIP)
Number of subjects: 81
Study 26983578 — intervention group
Group type: COMPARATOR
Intervention: Usual-care enhanced by two attention‐control telephone calls (Control)
Number of subjects: 81
Study 25160516 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Support Grant (CSG) application
Number of subjects: 3494
Study 21960110 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin/cyclophosphamide (AC) followed by docetaxel (Doc)
Number of subjects: 257
Study 21960110 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin/pemetrexed (AP) followed by docetaxel (Doc)
Number of subjects: 257
Study 21960110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone receptor-positive subgroup
Number of subjects: 257
Study 21960110 — intervention group
Group type: COMPARATOR
Intervention: CD24 3'UTR (TG/Del) genotype
Number of subjects: 257
Study 19642984 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Needs Assessment Tool (DNAT) plus diabetes learning modules
Number of subjects: 0
Study 19642984 — intervention group
Group type: COMPARATOR
Intervention: Diabetes learning modules alone (control group)
Number of subjects: 0
Study 19642984 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DNAT and control)
Number of subjects: 0
Study 17132650 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (50 microg bolus before wiring of each lesion)
Number of subjects: 62
Study 17132650 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (no adenosine pretreatment)
Number of subjects: 62
Study 15918933 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty with or without stent placement (CAS)
Number of subjects: 1154
Study 15918933 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1154
Study 12669445 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sclerotherapy (5% Sodium Morrhate + Triamcinolone Acetonide)
Number of subjects: 138
Study 12669445 — intervention group
Group type: COMPARATOR
Intervention: Traditional Sclerotherapy (5% Sodium Morrhate)
Number of subjects: 138
Study 10022415 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment, acute (4-5 hours)
Number of subjects: 0
Study 10022415 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment, short-term (5 days)
Number of subjects: 0
Study 7767194 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric chamber treatment at 193 mbar for 1 hour
Number of subjects: 31
Study 7767194 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (8 mg initially, followed by 4 mg after 6 hours)
Number of subjects: 31
Study 2312782 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine sulfate 200 mg orally every 8 hours for 24 hours prior to antipyrine administration
Number of subjects: 6
Study 2312782 — intervention group
Group type: COMPARATOR
Intervention: Antipyrine 1 gram dose alone
Number of subjects: 6
Study 2312782 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine sulfate
Number of subjects: 6
Study 6774845 — intervention group
Group type: EXPERIMENTAL
Intervention: 5700 rad in 19 treatments, 24 days overall
Number of subjects: 74
Study 6774845 — intervention group
Group type: COMPARATOR
Intervention: 4580 rad in 10 treatments, 11 days overall
Number of subjects: 74
Study 31628783 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 710 (5 mg/kg intravenously over 2 hours)
Number of subjects: 150
Study 31628783 — intervention group
Group type: COMPARATOR
Intervention: Infliximab US (5 mg/kg intravenously over 2 hours)
Number of subjects: 150
Study 31628783 — intervention group
Group type: COMPARATOR
Intervention: Infliximab EU (5 mg/kg intravenously over 2 hours)
Number of subjects: 150
Study 31628783 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 710
Number of subjects: 150
Study 31628783 — intervention group
Group type: COMPARATOR
Intervention: Infliximab US
Number of subjects: 150
Study 31628783 — intervention group
Group type: COMPARATOR
Intervention: Infliximab EU
Number of subjects: 150
Study 31628783 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 710, infliximab US, infliximab EU
Number of subjects: 150
Study 31277259 — intervention group
Group type: EXPERIMENTAL
Intervention: Guava fruit extract prepared by supercritical CO2 extraction
Number of subjects: 31
Study 31277259 — intervention group
Group type: COMPARATOR
Intervention: Control group (glucose solution)
Number of subjects: 31
Study 29390538 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy (35 to 45 minutes, 2 times/week for 12 weeks)
Number of subjects: 90
Study 29390538 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug therapy only
Number of subjects: 90
Study 26282635 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 346
Study 23895758 — intervention group
Group type: EXPERIMENTAL
Intervention: Hook plate fixation
Number of subjects: 105
Study 23895758 — intervention group
Group type: COMPARATOR
Intervention: Suture-anchor fixation
Number of subjects: 105
Study 21978192 — intervention group
Group type: EXPERIMENTAL
Intervention: acuPRP (manual acupuncture before PRP treatment)
Number of subjects: 34
Study 21978192 — intervention group
Group type: COMPARATOR
Intervention: Control (no acupuncture before PRP treatment)
Number of subjects: 34
Study 19210162 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI strategy with NNRTI-resistance mutation detected by ultra-deep sequencing
Number of subjects: 1397
Study 19210162 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI strategy with NNRTI-resistance mutation detected by standard and ultra-deep sequencing
Number of subjects: 1397
Study 19210162 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI strategy with mutation(s) detected only with ultra-deep sequencing
Number of subjects: 1397
Study 19210162 — intervention group
Group type: COMPARATOR
Intervention: NNRTI strategy without NNRTI-resistance mutations
Number of subjects: 1397
Study 17074704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative assessment structure in problem-based learning (PBL) tutorials
Number of subjects: 0
Study 17074704 — intervention group
Group type: COMPARATOR
Intervention: Individual, lecture-based learning
Number of subjects: 0
Study 17074704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative assessment structure in PBL
Number of subjects: 0
Study 15501951 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted clinical trial design
Number of subjects: 0
Study 15501951 — intervention group
Group type: COMPARATOR
Intervention: Untargeted clinical trial design
Number of subjects: 0
Study 10342783 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium mineral salt (19% reduction in urinary sodium)
Number of subjects: 86
Study 10342783 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12% increase in urinary sodium)
Number of subjects: 86
Study 8949759 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal neutron/photon irradiation (15 NGy + 18 PhGy)
Number of subjects: 96
Study 8949759 — intervention group
Group type: COMPARATOR
Intervention: Conformal photon irradiation (25 patients/78 Gy and 24 patients/83 Gy minimum dose)
Number of subjects: 96
Study 1997131 — intervention group
Group type: EXPERIMENTAL
Intervention: 55 micrograms Se/d as Se-rich meat or bread
Number of subjects: 24
Study 1997131 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 micrograms Se/d as Se-rich meat or bread
Number of subjects: 24
Study 1997131 — intervention group
Group type: EXPERIMENTAL
Intervention: 215 micrograms Se/d as Se-rich meat or bread
Number of subjects: 24
Study 1997131 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsupplemented subjects)
Number of subjects: 24
Study 1997131 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Se meat
Number of subjects: 24
Study 1997131 — intervention group
Group type: EXPERIMENTAL
Intervention: All Se intake levels
Number of subjects: 24
Study 1997131 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 24
Study 6119443 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole alone
Number of subjects: 43
Study 6119443 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole with framycetin and colistin
Number of subjects: 43
Study 31358685 — intervention group
Group type: EXPERIMENTAL
Intervention: Productive Ward: Releasing Time to Care programme
Number of subjects: 0
Study 31104760 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (received description of diagnostic criteria)
Number of subjects: 126
Study 31104760 — intervention group
Group type: COMPARATOR
Intervention: Group B (no description of diagnostic criteria)
Number of subjects: 126
Study 27278921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) 1000-1500 mg iron
Number of subjects: 252
Study 27278921 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulfate (FS) 200 mg iron/day
Number of subjects: 252
Study 27278921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 252
Study 27278921 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulfate (FS)
Number of subjects: 252
Study 25451910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic diabetes risk reduction intervention
Number of subjects: 59
Study 22352931 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg diazepam and 10 mg/kg ketamine (Parnell Laboratories NZ Ltd)
Number of subjects: 30
Study 22352931 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/kg diazepam and 10 mg/kg ketamine (Ketalar; Hospira NZ Ltd)
Number of subjects: 30
Study 22352931 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg/kg medetomidine and 2 mg/kg alphaxalone
Number of subjects: 30
Study 20496741 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 19
Study 20496741 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture combined with bloodletting therapy
Number of subjects: 19
Study 20496741 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with western medicine (e.g., catgut embedding therapy with Fluoxetine, electroacupuncture with Seroxat)
Number of subjects: 19
Study 17688075 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference formulation (40 mg pantoprazole enteric coated tablets) under fasting condition
Number of subjects: 98
Study 17688075 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (40 mg pantoprazole enteric coated tablets) under fasting condition
Number of subjects: 98
Study 17688075 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (40 mg pantoprazole enteric coated tablets) under fed condition
Number of subjects: 98
Study 17688075 — intervention group
Group type: COMPARATOR
Intervention: Test formulation (40 mg pantoprazole enteric coated tablets) under fed condition
Number of subjects: 98
Study 16081748 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent self-reported home safety practices (smoke detectors, bike helmets, car seats, water heater temperature)
Number of subjects: 0
Study 16081748 — intervention group
Group type: EXPERIMENTAL
Intervention: Car seat types
Number of subjects: 0
Study 16081748 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported practices (owning a car seat, hot water temperatures)
Number of subjects: 0
Study 16081748 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported practices (working smoke detectors, properly fitting bike helmets)
Number of subjects: 0
Study 12353900 — intervention group
Group type: EXPERIMENTAL
Intervention: PCCC with optic capture of the PC IOL (Group B)
Number of subjects: 34
Study 12353900 — intervention group
Group type: COMPARATOR
Intervention: ACCC with PCCC without optic capture of the PC IOL (Group A)
Number of subjects: 34
Study 12353900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 10075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 422
Study 10075140 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 422
Study 8602475 — intervention group
Group type: EXPERIMENTAL
Intervention: Jamar dynamometer
Number of subjects: 360
Study 8602475 — intervention group
Group type: EXPERIMENTAL
Intervention: Martin vigorimeter
Number of subjects: 360
Study 2140346 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 18
Study 2140346 — intervention group
Group type: COMPARATOR
Intervention: Control (resting quietly)
Number of subjects: 18
Study 7044913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB)
Number of subjects: 50
Study 7044913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50